Literature DB >> 19037637

Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls.

S A Eshuis1, P L Jager, R P Maguire, S Jonkman, R A Dierckx, K L Leenders.   

Abstract

PURPOSE: Diagnosing Parkinson's disease (PD) on clinical grounds may be difficult, especially in the early stages of the disease. F-DOPA PET and FP-CIT SPECT scans are able to determine presynaptic dopaminergic activity in different ways. The aim of this study was to determine and compare the sensitivity and specificity of the two methods in the detection of striatal dopaminergic deficits in the same cohort of PD patients and healthy controls.
METHODS: Movement disorder specialists recruited 11 patients with early-stage PD and 17 patients with advanced PD. The patients underwent both an FP-CIT SPECT scan and an F-DOPA PET scan. In addition, 10 FP-CIT SPECT scans or 10 F-DOPA PET scans were performed in 20 healthy controls. A template with regions of interest was used to sample tracer activity of the caudate, putamen and a reference region in the brain. The outcome parameter was the striatooccipital ratio (SOR). Normal SOR values were determined in the controls. The sensitivity and specificity of both scanning methods were calculated.
RESULTS: FP-CIT SPECT and F-DOPA PET scans were both able to discriminate PD patients from healthy controls. For the early phases of the disease, sensitivity and specificity of the contralateral striatal and putaminal uptake of FP-CIT and F-DOPA was 100%. When only caudate uptake was considered, the specificities were 100% and 90% for FP-CIT and F-DOPA, respectively, while the sensitivity was 91% for both scanning techniques.
CONCLUSION: FP-CIT SPECT and F-DOPA PET scans are both able to diagnose presynaptic dopaminergic deficits in early phases of PD with excellent sensitivity and specificity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19037637     DOI: 10.1007/s00259-008-0989-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  47 in total

1.  Dopamine transporters decrease with age.

Authors:  N D Volkow; Y S Ding; J S Fowler; G J Wang; J Logan; S J Gatley; R Hitzemann; G Smith; S D Fields; R Gur
Journal:  J Nucl Med       Date:  1996-04       Impact factor: 10.057

2.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

Authors:  K L Leenders; A J Palmer; N Quinn; J C Clark; G Firnau; E S Garnett; C Nahmias; T Jones; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

3.  Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.

Authors:  J Booij; P Bergmans; A Winogrodzka; J D Speelman; E C Wolters
Journal:  Synapse       Date:  2001-02       Impact factor: 2.562

4.  Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.

Authors:  T Ishikawa; V Dhawan; T Chaly; C Margouleff; W Robeson; J R Dahl; F Mandel; P Spetsieris; D Eidelberg
Journal:  J Nucl Med       Date:  1996-02       Impact factor: 10.057

5.  Clinical and [18F] dopa PET findings in early Parkinson's disease.

Authors:  P K Morrish; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

6.  Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography.

Authors:  E S Garnett; C Nahmias; G Firnau
Journal:  Can J Neurol Sci       Date:  1984-02       Impact factor: 2.104

7.  A new model for separation between brain dopamine and serotonin transporters in 123I-beta-CIT SPECT measurements: normal values and sex and age dependence.

Authors:  Erik Ryding; Mats Lindström; Björn Brådvik; Martin Grabowski; Peter Bosson; Lil Träskman-Bendz; Ingmar Rosén
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-11       Impact factor: 9.236

8.  Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.

Authors:  R B Innis; J P Seibyl; B E Scanley; M Laruelle; A Abi-Dargham; E Wallace; R M Baldwin; Y Zea-Ponce; S Zoghbi; S Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

9.  Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum.

Authors:  John W Haycock; Laurence Becker; Lee Ang; Yoshiaki Furukawa; Oleh Hornykiewicz; Stephen J Kish
Journal:  J Neurochem       Date:  2003-11       Impact factor: 5.372

10.  Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.

Authors:  A Antonini; P Vontobel; M Psylla; I Günther; P R Maguire; J Missimer; K L Leenders
Journal:  Arch Neurol       Date:  1995-12
View more
  33 in total

1.  In vitro and initial in vivo evaluation of (68)Ga-labeled transferrin receptor (TfR) binding peptides as potential carriers for enhanced drug transport into TfR expressing cells.

Authors:  Carmen Wängler; Dina Nada; Georg Höfner; Simone Maschauer; Björn Wängler; Stephan Schneider; Esther Schirrmacher; Klaus T Wanner; Ralf Schirrmacher; Olaf Prante
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

2.  The role of the deep convolutional neural network as an aid to interpreting brain [18F]DOPA PET/CT in the diagnosis of Parkinson's disease.

Authors:  Arnoldo Piccardo; Roberto Cappuccio; Gianluca Bottoni; Diego Cecchin; Luca Mazzella; Alessio Cirone; Sergio Righi; Martina Ugolini; Pietro Bianchi; Pietro Bertolaccini; Elena Lorenzini; Michela Massollo; Antonio Castaldi; Francesco Fiz; Laura Strada; Angelina Cistaro; Massimo Del Sette
Journal:  Eur Radiol       Date:  2021-03-08       Impact factor: 5.315

3.  Clinical Significance of F-18 FP-CIT Dual Time Point PET Imaging in Idiopathic Parkinson's Disease.

Authors:  Jin Kyoung Oh; Ik Dong Yoo; Ye Young Seo; Yong An Chung; Ie Ryung Yoo; Sung Hoon Kim; In Uk Song
Journal:  Nucl Med Mol Imaging       Date:  2011-10-14

4.  Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease.

Authors:  Agnese Picco; Silvia Morbelli; Arnoldo Piccardo; Dario Arnaldi; Nicola Girtler; Andrea Brugnolo; Irene Bossert; Lucio Marinelli; Antonio Castaldi; Fabrizio De Carli; Claudio Campus; Giovanni Abbruzzese; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-28       Impact factor: 9.236

Review 5.  Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.

Authors:  Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat
Journal:  Dtsch Arztebl Int       Date:  2019-11-01       Impact factor: 5.594

6.  Comparison of 18F PET and 99mTc SPECT imaging in phantoms and in tumored mice.

Authors:  Dengfeng Cheng; Yi Wang; Xinrong Liu; P Hendrik Pretorius; Minmin Liang; Mary Rusckowski; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2010-08-18       Impact factor: 4.774

Review 7.  Imaging approaches for dementia.

Authors:  A D Murray
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-01       Impact factor: 3.825

8.  Validation of Simple Quantification Methods for (18)F-FP-CIT PET Using Automatic Delineation of Volumes of Interest Based on Statistical Probabilistic Anatomical Mapping and Isocontour Margin Setting.

Authors:  Yong-Il Kim; Hyung-Jun Im; Jin Chul Paeng; Jae Sung Lee; Jae Seon Eo; Dong Hyun Kim; Euishin E Kim; Keon Wook Kang; June-Key Chung; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2012-08-02

9.  Recent imaging advances in the diagnosis and management of Parkinson's disease.

Authors:  David J Brooks; Nicola Pavese
Journal:  F1000 Med Rep       Date:  2009-10-29

10.  The sensitivity and specificity of F-DOPA PET in a movement disorder clinic.

Authors:  Nevein Ibrahim; Joanna Kusmirek; Aaron F Struck; John M Floberg; Scott B Perlman; Catherine Gallagher; Lance T Hall
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.